Analysis of the demographic structure of patients undergoing preventive examinations during the European Prevention Program for HNC in the last 10 years Original article

Article Sidebar

PDF (Język Polski)


Published: Oct 2, 2023
DOI: https://doi.org/10.24292/01.AP.192150923
Keywords:
head and neck cancer, preventive examinations, risk factors

Main Article Content

Rafał Jowik
1. Zakład Otolaryngologii, Instytut Nauk Medycznych, Collegium Medicum UKSW w Warszawie. 2. Oddział Otolaryngologii, Międzyleski Szpital Specjalistyczny w Warszawie
http://orcid.org/0009-0006-7990-453X
Wiktor Dżaman
1. Zakład Otolaryngologii, Instytut Nauk Medycznych, Collegium Medicum UKSW w Warszawie. 2. Oddział Otolaryngologii, Międzyleski Szpital Specjalistyczny w Warszawie
http://orcid.org/0009-0002-1137-5193
Wiktoria Mercedes Ernst
1. Zakład Otolaryngologii, Instytut Nauk Medycznych, Collegium Medicum UKSW w Warszawie. 2. Oddział Otolaryngologii, Międzyleski Szpital Specjalistyczny w Warszawie
https://orcid.org/0009-0006-6598-847X
Karolina Piskadło-Zborowska
1. Zakład Otolaryngologii, Instytut Nauk Medycznych, Collegium Medicum UKSW w Warszawie. 2. Oddział Otolaryngologii, Międzyleski Szpital Specjalistyczny w Warszawie
http://orcid.org/0000-0003-1149-7393

Abstract

Introduction: Since 2013, every September, the European Head and Neck Cancer Prevention Week (HNC) has been held to promote the best practices in the prevention, diagnosis and treatment of HNC. During this time in Europe, patients can take advantage of free ENT examinations.
Aim: Analysis of the demographic structure of patients undergoing preventive examinations during the European Prevention Program for HNC at ENT Department in the last 10 years.
Material and method: In 2013 2022, 2125 patients (aged 21 to 93, av. 61 years) were examined during the European Head and Neck Cancer Prevention Week. Women accounted for 69% of patients (n = 1466), and men for 31% (n = 659). Patients filled out a questionnaire regarding both HNC risk factors and symptoms but also lifestyle. They underwent ENT examinations and, if necessary, additional diagnostics (nasopharyngeal and laryngeal fiberoscopy, imaging and histopathological examinations).
Results: Women attendant to the screening program more often and earlier than men. Only 13% were patients under 45 years of age. The most common risk factors for HNC were: smoking (24%), infrequent dental check-ups (28%) and prosthetic restorations (43%). The main reasons for applying for screening were dry mouth, chronic hoarseness and a family history of cancer. Oncological lesions were detected in 90 patients and precancerous lesions in 22 patients. Of the malignant tumors, 89% were clinically advanced.
Discussion: Preventive examinations of HNC are crucial for early detection and treatment of the diseases and for improving social awareness of risk factors.
Conclusions: The prophylactic program allowed for early treatment of inflammation, precancerous lesions and cancer in 170 people.

Downloads

Download data is not yet available.

Article Details

How to Cite
Jowik, R., Dżaman, W., Ernst, W. M., & Piskadło-Zborowska, K. (2023). Analysis of the demographic structure of patients undergoing preventive examinations during the European Prevention Program for HNC in the last 10 years. Alergoprofil, 19(2), 13-19. https://doi.org/10.24292/01.AP.192150923
Issue
Vol 19 No 2 (2023)
Section
THERAPY
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Reich M, Licitra L, Vermorken JB et al. Best practice guidelines in the psychosocial management of HPV-related head and neck cancer: recommendations from the European Head and Neck Cancer Society’s Make Sense Campaign. Ann Oncol. 2016; 27: 1848-54.
2. Dzaman K, Piskadlo-Zborowska K, Pietniczka-Zaleska M. Analysis of implementiation of 4th Head and Neck Cancer Awareness Week in Department of Otolaryngology in Miedzyleski Hospital in Warsaw. Otolaryngol Pol. 2017; 71: 33-7.
3. Gormley M, Creaney G, Schache A et al. Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors. Br Dent J. 2022; 233: 780-6.
4. Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71: 209-49.
5. Rettig EM, D’Souza G. Epidemiology of head and neck cancer. Surg Oncol Clin N Am. 2015; 24: 379-96.
6. Gillison ML, Chaturvedi AK, Anderson WF et al. Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. J Clin Oncol. 2015; 33: 3235-42.
7. Wierzbicka M, Klussmann JP, San Giorgi MR et al. Oral and laryngeal HPV infection: Incidence, prevalence and risk factors, with special regard to concurrent infection in head, neck and genitals. Vaccine. 2021; 39: 2344-50.
8. Miranda-Filho A, Bray F. Global patterns and trends in cancers of the lip, tongue and mouth. Oral Oncol. 2020; 102: 104551.
9. Jurkiewicz D, Dzaman K, Rapiejko P. [Laryngeal cancer risk factors]. Pol Merkur Lekarski. 2006; 21: 94-8.
10. Kawakita D, Matsuo K. Alcohol and head and neck cancer. Cancer Metastasis Rev. 2017; 36: 425-34.
11. Schache AG, Powell NG, Cuschieri KS et al. HPV-Related Oropharynx Cancer in the United Kingdom: An Evolution in the Understanding of Disease Etiology. Cancer Res. 2016; 76: 6598-606.
12. Mehanna H, Franklin N, Compton N et al. Geographic variation in human papillomavirus-related oropharyngeal cancer: Data from 4 multinational randomized trials. Head Neck. 2016; 38(suppl 1): E1863-9.
13. Cohen N, Fedewa S, Chen AY. Epidemiology and Demographics of the Head and Neck Cancer Population. Oral Maxillofac Surg Clin North Am. 2018; 30: 381-95.
14. Shield KD, Ferlay J, Jemal A et al. The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012. CA Cancer J Clin. 2017; 67: 51-64.
15. Verdonck-de Leeuw I, Dawson C, Licitra L et al. European Head and Neck Society recommendations for head and neck cancer survivorship care. Oral Oncol. 2022; 133: 106047.
16. Crowder SL, Najam N, Sarma KP et al. Quality of life, coping strategies, and supportive care needs in head and neck cancer survivors: a qualitative study. Support Care Cancer. 2021; 29: 4349-56.
17. Taylor KJ, Amdal CD, Bjordal K et al. Serious Long-Term Effects of Head and Neck Cancer from the Survivors’ Point of View. Healthcare (Basel). 2023; 11: 906.
18. Vigano A, De Felice F, Iacovelli NA et al. Quality of life changes over time and predictors in a large head and neck patients’ cohort: secondary analysis from an Italian multi-center longitudinal, prospective, observational study-a study of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) head and neck working group. Support Care Cancer. 2023; 31: 220.
19. Pytel A, Zielinska A, Stas J, Chabowski M. Quality of Life, Psychological Distress, and Nutritional Status of Polish Patients with Head and Neck Cancer Treated with Radiotherapy. J Clin Med. 2023; 12: 659.
20. Johnson DE, Burtness B, Leemans CR et al. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020; 6: 92.
21. Svider PF, Blasco MA, Raza SN et al. Head and Neck Cancer. Otolaryngol Head Neck Surg. 2017; 156: 10-3.
22. Spector ME, Farlow JL, Haring CT et al. The potential for liquid biopsies in head and neck cancer. Discov Med. 2018; 25: 251-7.
23. Kabzinski J, Kucharska-Lusina A, Majsterek I. RNA-Based Liquid Biopsy in Head and Neck Cancer. Cells. 2023; 12: 1916.
24. Kim JK, Leeman JE, Riaz N et al. Proton Therapy for Head and Neck Cancer. Curr Treat Options Oncol. 2018; 19: 28.
25. Domka W, Bartusik-Aebisher D, Mytych W et al. The Use of Photodynamic Therapy for Head, Neck, and Brain Diseases. Int J Mol Sci. 2023; 24: 11867.
26. Bicci E, Nardi C, Calamandrei L et al. Magnetic resonance imaging in naso-oropharyngeal carcinoma: role of texture analysis in the assessment of response to radiochemotherapy, a preliminary study. Radiol Med. 2023; 128: 839-52.
27. Wierzbicka M, Fijuth J, Skladowski K et al. Adjuvant radiotherapy in parotid gland pleomorphic adenoma – recommendations. Otolaryngol Pol. 2022; 76: 1-7.